Superworth

Orthopediatrics KIDS

Medical - Instruments & Supplies, Healthcare
$24.50
−0.85%
Market cap
$639.7M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
2.5×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$252.7M
+14% on a year ago
Net margin
−15.7%
Free cash flow yield
−0.3%

Orthopediatrics trades at 2.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $252.7M over the last twelve months, up 14% on a year earlier with a −16% net margin.

Charts

Financials

Income statement for KIDS, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$40M+14%$37.6M+21%$44.7M+42%$52.8M+34%$54.6M+37%$52.7M+40%$52.4M+17%$61.1M+16%$61.3M+12%$61.6M+17%$59.4M+13%$70.5M+15%
Cost of revenue$9M−1%$10.9M+12%$12.5M+56%$12M+26%$14.5M+61%$17.1M+57%$14.1M+13%$17.1M+42%$16M+10%$16.5M−4%$16M+13%$18.1M+6%
Gross profit$31M+20%$26.7M+26%$32.2M+37%$40.8M+36%$40.1M+29%$35.6M+33%$38.3M+19%$44M+8%$45.3M+13%$45.1M+27%$43.4M+13%$52.4M+19%
R&D$2.6M+16%$2.9M+44%$3M+23%$2.5M−14%$2.6M+1%$2.9M−0%$2.4M−22%$2.2M−15%$2.3M−10%$2.3M−23%$2.2M−5%$2.3M+8%
SG&A$31.9M+18%$31.9M+16%$38.9M+31%$43.9M+35%$43M+35%$41.2M+29%$46.9M+20%$49.5M+13%$47.8M+11%$48.4M+17%$49.5M+6%$54.1M+9%
−$4.5M−35%−$8.1M−3%−$9.7M+13%−$5.7M+1%−$5.6M+24%−$14.1M+74%−$11M+13%−$10.7M+88%−$9.4M+69%−$8.2M−42%−$8.3M−24%−$4.1M−62%
Interest expense$21K−97%−$63K+3%$637K+5691%$261K−11%$404K+1824%$1.3M$1.1M+77%$1.1M+328%$1.8M+351%$1.9M+47%$2.1M+87%$2.5M+127%
Pre-tax income−$3.7M−$6.9M−13%−$10.3M+40%−$6M+84%−$9.1M+144%−$16.4M+138%−$10.5M+1%−$7.1M+17%−$11.9M+30%−$9.8M−41%−$10.9M+4%−$6.9M−2%
$849K−$212K+342%−$2.5M+341%−$18K−96%−$1.2M−$340K+60%$196K$49K−$125K−90%$340K−$171K$234K+378%
Net income−$4.6M−$6.7M−15%−$7.8M+15%−$6M+109%−$7.9M+73%−$16.1M+140%−$10.7M+37%−$7.1M+18%−$11.8M+49%−$10.1M−37%−$10.7M+0%−$7.2M+1%
−$0.20−$0.29−22%−$0.34+13%−$0.26+100%−$0.34+70%−$0.69+138%−$0.46+35%−$0.30+15%−$0.50+47%−$0.43−38%−$0.45−2%−$0.30+0%
22.8M+7%22.8M+10%22.8M+1%23.1M+2%23.2M+2%23.2M+2%23.2M+2%23.5M+1%23.6M+2%23.6M+2%23.7M+2%24M+3%

Net income: 4 periods, Q2 FY19 to Q2 FY20: not printed by the filing, worked out from its own lines.

EPS, diluted: 6 periods, Q4 FY16 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 9 periods, Q4 FY16 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Orthopediatrics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
KIDSOrthopediatrics$639.7Mn/m234×2.5×+14%−15.7%
MOVMovado$701.9M17.5×13.3×1.0×+5%6.0%
MDXGMimedx$569.9M97.8×21.1×1.6×−2%1.8%
TCMDTactile Systems Technology$535.5M21.9×62.9×1.5×+17%7.1%
EMBCEmbecta$380.2M4.6×11.7×0.4×−8%8.6%
IRMDIradimed$1.1B47.9×41.4×12.7×+11%26.7%
STAAStaar Surgical$1.1B323×143×3.3×+51%1.1%
BVSBioventus$1.3B19.4×27.2×2.2×+3%9.4%
CDRECadre$1.3B37.0×35.8×1.9×+20%5.3%
INFUInfuSystem$277.6M34.0×43.5×1.9×+2%6.0%
EYENational Vision$1.5B30.6×53.3×0.7×+8%2.5%
Peer median$899.7M32.3×38.6×1.7×+7%6.0%

More on Orthopediatrics

Each number over time

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .